Clinical data | |
---|---|
Routes of administration | By mouth |
ATC code |
|
Pharmacokinetic data | |
Bioavailability | 41% |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C18H19N3O2 |
Molar mass | 309.369 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
CGS-20625 is an anxiolytic drug used in scientific research. It has similar effects to benzodiazepine drugs, [1] but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. [2] [3] It produces anxiolytic and anticonvulsant effects, but with no sedative effects even at high doses, and no significant muscle relaxant effects. [4] It is orally active in humans, but with relatively low bioavailability. [5]
CGS-20625 is a positive allosteric modulator at several GABAA receptors types. Due to its alicyclic moiety potency at γ1 subunit, containing receptor types is more pronounced for CGS-20625 compared to benzodiazepines. [1] γ1 subunits are expressed at higher levels in the central amygdala. [6]
Clinical data | |
---|---|
Routes of administration | By mouth |
ATC code |
|
Pharmacokinetic data | |
Bioavailability | 41% |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C18H19N3O2 |
Molar mass | 309.369 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
CGS-20625 is an anxiolytic drug used in scientific research. It has similar effects to benzodiazepine drugs, [1] but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. [2] [3] It produces anxiolytic and anticonvulsant effects, but with no sedative effects even at high doses, and no significant muscle relaxant effects. [4] It is orally active in humans, but with relatively low bioavailability. [5]
CGS-20625 is a positive allosteric modulator at several GABAA receptors types. Due to its alicyclic moiety potency at γ1 subunit, containing receptor types is more pronounced for CGS-20625 compared to benzodiazepines. [1] γ1 subunits are expressed at higher levels in the central amygdala. [6]